May 21, 2020
US Dermatophytic Onychomycosis Drug Forecast and Market Analysis 2020-2028, Featuring Actavis, Allergan and Topica Pharmaceuticals
Apr 29, 2020
FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
Jan 22, 2020
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
Dec 12, 2019
Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
Oct 22, 2019
DermBiont Announces Positive Data from Phase 2a Clinical Trial and Start of Phase 2b Clinical Trial for Athlete's Foot with a Topical Live Biotherapeutic
Oct 21, 2019
Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea
Oct 15, 2019
United States Onychomycosis Market Size, Trends & Forecasts Report 2019-2023
Jul 25, 2019
Information Update - Laser-based medical devices not authorized to treat fungal nail infections
Mar 22, 2019
Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe
Nov 21, 2018
Blueberry Therapeutics Limited Announce Positive Results from a Phase I/II Clinical Trial
Sep 18, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
Aug 14, 2018
Blueberry Therapeutics Limited Closes £10m Funding to Support Development of Nanomedicines Portfolio
Jul 25, 2018
Epiomic Epidemiology Report: Onychomycosis Forecast In 22 Major Markets 2018-2028
Apr 30, 2018
Fungal Foot Infections Drug Development Pipeline Review 2018
Jan 15, 2018
Moberg Pharma Receives Favorable Outcome From NAD - Main Competitor to Discontinue Current Marketing